喜树碱衍生物的抗肿瘤研究进展  

Review on Development of New Camptothecin Derivatives as Antitumor Agents

作　　者：张磊[1] 张泽国[1] 王京[1] 

机构地区：[1]遵义医学院药学院,遵义563003

出　　处：《天然产物研究与开发》2016年第11期1830-1837,共8页Natural Product Research and Development

基　　金：贵州省科技厅基金(2014-7565;2014-7557;2015-6010)

摘　　要：喜树碱是一种重要的天然抗肿瘤药物,但是水溶性差、毒副作用较强及容易代谢失活等缺点限制了其作为临床抗肿瘤药物的应用。为了克服喜树碱的缺点,研究人员对其进行了数十年的结构修饰和改造工作,得到了许多活性更为优良的喜树碱类衍生物,如拓扑替康和伊立替康等。本文对2013-2016年间喜树碱衍生物的抗肿瘤研究进行了综述。Camptothecin is an important antitumor product from Camptotheca acuminata,however,the disadvantages,such as poor solubility,toxicity and metabolic inactivation,block its application as antineoplastic agent. Over the past few decades,the modifications of camptothecin have been carried out by numerous researchers to conquer its drawbacks,and many excellent camptothecin derivatives were developed,including topotecan and irinotecan. This review will highlight recent advances（ 2013-2016） in the development of new camptothecin derivatives as potential anticancer agents.

关 键 词：喜树碱 衍生物 抗肿瘤 

分 类 号：R979.1[医药卫生—药品]